Table 2.
Descriptive Characteristics of Adolescent and Adult MMR Recipients, Vaccine Safety Datalink, 2010-2018.a
| Characteristicb | Overall (N = 272,861) | Age Groupc | |||
|---|---|---|---|---|---|
|
9–17 Years (N = 36,674) |
18–25 Years (N = 43,633) |
26–44 Years (N = 124,397) |
≥45 Years (N = 68,157) |
||
| Sex | |||||
| Female | 179,657 (65.8) | 18,274 (49.8) | 31,191 (71.5) | 88,039 (70.8) | 42,153 (61.9) |
| Male | 93,204 (34.2) | 18,400 (50.2) | 12,442 (28.5) | 36,358 (29.2) | 26,004 (38.2) |
| Race/Ethnicity | |||||
| White, Non-Hispanic | 104,060 (38.1) | 12,852 (35.0) | 14,066 (32.2) | 43,122 (34.7) | 34,020 (49.9) |
| Hispanic, Any Race | 70,468 (25.8) | 10,135 (27.6) | 14,199 (32.5) | 35,141 (28.3) | 10,993 (16.1) |
| Asian, Non-Hispanic | 52,446 (19.2) | 4,893 (13.3) | 8,067 (18.5) | 27,440 (22.1) | 12,046 (17.7) |
| Multiracial, Non-Hispanic | 24,093 (8.8) | 4,761 (13.0) | 4,099 (9.4) | 9,755 (7.8) | 5,478 (8.0) |
| Black, Non-Hispanic | 16,698 (6.1) | 3,102 (8.5) | 2,268 (5.2) | 6,701 (5.4) | 4,627 (6.8) |
| Other/Unknown | 5,096 (1.9) | 931 (2.5) | 934 (2.1) | 2,238 (1.8) | 993 (1.5) |
| Received ≥ 1 Simultaneous Vaccine | |||||
| Yes | 145,244 (53.2) | 28,910 (78.8) | 22,472 (51.5) | 57,816 (46.5) | 36,046 (52.9) |
| No | 127,617 (46.8) | 7,764 (21.2) | 21,161 (48.5) | 66,581 (53.5) | 32,111 (47.1) |
| Vaccination Year | |||||
| 2010 | 18,379 (6.7) | 4,686 (12.8) | 3,048 (7.0) | 7,606 (6.1) | 3,039 (4.5) |
| 2011 | 22,113 (8.1) | 6,019 (16.4) | 3,713 (8.5) | 8,555 (6.9) | 3,826 (5.6) |
| 2012 | 21,136 (7.8) | 4,864 (13.3) | 3,734 (8.6) | 8,858 (7.1) | 3,680 (5.4) |
| 2013 | 19,586 (7.2) | 3,185 (8.7) | 3,849 (8.8) | 8,681 (7.0) | 3,871 (5.7) |
| 2014 | 23,271 (8.5) | 3,222 (8.8) | 4,338 (9.9) | 10,734 (8.6) | 4,977 (7.3) |
| 2015 | 42,216 (15.5) | 4,409 (12.0) | 5,902 (13.5) | 18,813 (15.1) | 13,092 (19.2) |
| 2016 | 43,469 (15.9) | 3,675 (10.0) | 6,378 (14.6) | 21,079 (16.9) | 12,337 (18.1) |
| 2017 | 43,684 (16.0) | 3,711 (10.1) | 6,679 (15.3) | 20,931 (16.8) | 12,363 (18.1) |
| 2018 | 39,007 (14.3) | 2,903 (7.9) | 5,992 (13.7) | 19,140 (15.4) | 10,972 (16.1) |
| Dose Numberd | |||||
| 1 | 175,655 (64.4) | 11,229 (30.6) | 17,168 (39.4) | 93,733 (75.4) | 53,535 (78.5) |
| 2 | 68,555 (25.1) | 19,198 (52.4) | 9,546 (21.9) | 25,638 (20.6) | 14,173 (20.8) |
| 3 | 24,781 (9.1) | 5,875 (16.0) | 14,276 (32.7) | 4,225 (3.4) | 405 (0.6) |
| ≥4e | 3,870 (1.4) | 372 (1.0) | 2,643 (6.1) | 801 (0.6) | 54 (0.1) |
| Time Since Last Dose in Years, median (IQR)f | 8.6 (0.5–15.4) | 9.5 (4.7–12.2) | 15.6 (9.5–18.1) | 2.9 (0.1–16.9) | 0.4 (0.1–5.4) |
| Length of VSD Enrollmentg | |||||
| <1 Year | 47,531 (17.4) | 7,645 (20.9) | 8,500 (19.5) | 24,833 (20.0) | 6,553 (9.6) |
| 1–2 Years | 68,368 (25.1) | 10,367 (28.3) | 10,426 (23.9) | 36,781 (29.6) | 10,794 (15.8) |
| 3–4 Years | 39,661 (14.5) | 6,259 (17.1) | 5,545 (12.7) | 20,394 (16.4) | 7,463 (11.0) |
| 5–9 Years | 53,464 (19.6) | 8,152 (22.2) | 7,186 (16.5) | 25,182 (20.2) | 12,944 (19.0) |
| ≥10 Years | 63,837 (23.4) | 4,251 (11.6) | 11,976 (27.5) | 17,207 (13.8) | 30,403 (44.6) |
| ≥1 Possible Indication Identifiedh | |||||
| Yes | 88,933 (32.6) | 32,481 (88.6) | 9,091 (20.8) | 36,182 (29.1) | 11,179 (16.4) |
| No | 183,928 (67.4) | 4,193 (11.4) | 34,542 (79.2) | 88,215 (70.9) | 56,978 (83.6) |
| Postpartumi | |||||
| Yes | 31,916 (17.8) | 330 (1.8) | 8,049 (25.8) | 23,488 (26.7) | 49 (0.1) |
| No | 147,741 (82.2) | 17,944 (98.2) | 23,142 (74.2) | 64,551 (73.3) | 42,104 (99.9) |
| ≥1 Travel Vaccine Simultaneously Administeredj | |||||
| Yes | 25,141 (9.2) | 268 (0.7) | 1,044 (2.4) | 12,699 (10.2) | 11,130 (16.3) |
| No | 247,720 (90.8) | 36,406 (99.3) | 42,589 (97.6) | 111,698 (89.8) | 57,027 (83.7) |
Aaabbreviations: MMR = measles, mumps, and rubella vaccine; IQR = interquartile range; VSD = Vaccine Safety Datalink.
Unit of analysis is vaccine dose not unique individual.
Characteristics are presented as number (column percentage) unless otherwise specified. Percentages may not add to 100.0% due to rounding.
Age group is based on age in years at the time of MMR administration.
Dose number is based on all available VSD electronic data on MMR-containing vaccines; full vaccination history may not be captured for all members, especially vaccines received prior to VSD enrollment.
Includes dose number 4–9. The vast majority of those classified as receiving ≥ 4 doses received a fourth dose (n = 3,474, 89.8 %).
Time since last dose of MMR-containing vaccine is missing for those that received a first dose during the study period.
Length of VSD enrollment is defined as the number of years of continuous VSD enrollment at the time of MMR administration.
Possible indication for MMR receipt identified from electronic data; indications include rubella seronegative status (females only), international travel, and catch-up vaccination (adolescents only).
Postpartum status is based on VSD electronic data and only applies to female vaccinees. Postpartum status is used as a proxy for rubella seronegative status.
Includes vaccines solely indicated for international travel: cholera, Japanese encephalitis, typhoid, and yellow fever.